Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. The company's marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. The company is evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia.
  • TickerVRTX
  • ISINUS92532F1003
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

An unfavourable environment weighs on VERTEX PHARMA INC, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of VERTEX PHARMA INC (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date June 1, 2021, the closing price was USD 209.67 and its target price was estimated at USD 178.56.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

MarketLine Department

Astex Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Astex Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Astex Pharmaceuticals, Inc. (Astex or 'the company'), a member of Otsuka Group, discovers, develops and commercializes cancer and central nervous system (CNS) therapies. It offers oncology product portfolio with multiple drugs in mid-late stage clinical development worldwide and ...

Valens Research

Valens Equity Insights and Inflections - 2020 11 17

NFLX currently trades above corporate averages relative to Uniform earnings, with a 44.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to improve from 24% in 2019 to 31% in 2024, accompanied by 28% Uniform asset growth going forward. Meanwhile, analysts have even more bullish expectations, projecting Uniform ROA to expand to 37% by 2021, accompanied by 8% Uniform asset growth. However, management appears concerned about growth, cash flows, and churn. Current valuations appear to be pricing in overly bullish expectations for NFLX, and if the company is not...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, when the KBW Bank index broke below key $89 support we outlined last week. Friday's widening move in h...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weigh...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

MarketLine Department

Astex Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Astex Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Astex Pharmaceuticals, Inc. (Astex or 'the company'), a member of Otsuka Group, discovers, develops and commercializes cancer and central nervous system (CNS) therapies. It offers oncology product portfolio with multiple drugs in mid-late stage clinical development worldwide and ...

Valens Research

Valens Equity Insights and Inflections - 2020 11 17

NFLX currently trades above corporate averages relative to Uniform earnings, with a 44.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to improve from 24% in 2019 to 31% in 2024, accompanied by 28% Uniform asset growth going forward. Meanwhile, analysts have even more bullish expectations, projecting Uniform ROA to expand to 37% by 2021, accompanied by 8% Uniform asset growth. However, management appears concerned about growth, cash flows, and churn. Current valuations appear to be pricing in overly bullish expectations for NFLX, and if the company is not...

An unfavourable environment weighs on VERTEX PHARMA INC, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of VERTEX PHARMA INC (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date June 1, 2021, the closing price was USD 209.67 and its target price was estimated at USD 178.56.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch